And not just GVHD. Cynata and Cymerus is a platform technology. OA P3, regardless if it is a TGA or FDA trial will only strengthen CYPs bargaining power. Build enough undeniable data while cell therapy landscape and industry appetite increases, then it will be much easier for peers to identify value. "ohh a competitor with a Gen 1 tech is $3B and CYP is only $50M.... a $500M TO would be a steal"
CYP Price at posting:
23.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)